PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics based on its proprietary INTASYL self-delivering RNAi technology platform. Headquartered in Marlborough, Massachusetts, the clinical-stage biotechnology company focuses on creating targeted therapeutic compounds that silence genes associated with disease expression. The company's lead product candidate, PH-762, targets checkpoint protein PD-1 and is being developed for adoptive cell therapy in multiple cancer types. Phio's INTASYL platform enables the delivery of RNA interference compounds directly into cells without the need for specialized delivery vehicles, potentially offering advantages in stability and manufacturing compared to conventional RNAi approaches. The company's pipeline includes programs targeting solid tumors through both direct administration and ex vivo cell therapy applications. In recent years, Phio has pursued strategic collaborations and licensing agreements to advance its technology platform and expand therapeutic applications. The company operates as a development-stage enterprise, conducting preclinical and clinical research to validate its approach to gene silencing in cancer treatment. Phio maintains intellectual property protection through patents covering its INTASYL technology and specific therapeutic applications. As a publicly traded entity on the Nasdaq Capital Market under ticker symbol PHIO, the company funds operations through equity financings while advancing its clinical programs and exploring partnership opportunities in the immuno-oncology space.